Please login to the form below

Not currently logged in
Email:
Password:

Amgen, GSK to commercialise denosumab

Amgen and GSK are to collaborate and share the commercialisation of Amgen's denosumab for postmenopausal osteoporosis

Amgen and GlaxoSmithKline (GSK) are to collaborate and share the commercialisation of Amgen's monoclonal antibody denosumab for postmenopausal osteoporosis (PMO).

Amgen will commercialise the monoclonal antibody denosumab for PMO and oncology in the US and Canada and for all oncology indications in Europe and specified markets.

GSK will register and commercialise denosumab for all indications in countries where Amgen does not already have a commercial presence, including China, Brazil, India and South Korea.

Amgen will receive an initial payment and near-term commercial milestones totalling $120m, and ongoing royalties. In Europe, Amgen and GSK will share profits after accounting for expenses associated with the partnership. In emerging markets, GSK will be responsible for all expenses and purchase denosumab from Amgen to meet demand.

"Our collaboration with GSK will help Amgen bring the promise of denosumab to patients in Europe and other parts of the world more effectively than if we commercialised the drug globally on our own," said Amgen CEO Kevin Sharer.

"This pioneering treatment will be a strong addition to our biopharmaceuticals portfolio," commented Andrew Witty, CEO of GSK. "The data for denosumab is very encouraging and we believe it will provide significant benefit and value to patients with PMO and other bone disease conditions."

Earlier this year, Amgen granted Daiichi Sankyo exclusive rights to develop and commercialise denosumab in Japan in PMO and oncology with the potential for additional indications. This arrangement remains in place.

The news broke at the same time that Amgen posted its second-quarter figures of $1.3 billion – up 40 per cent from 2008, in part due to favourable sales of its arthritis drug Enbrel. Sharer said: "We are optimistic about our financial performance in 2009 and are focusing on making denosumab a success."

28th July 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fendix

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics